Orbital Fat-Derived Mesenchymal Cells for Oxidative-Stress RPE Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD), particularly non-neovascular AMD, are limited to slowing disease progression and do not reverse damage to the macula, while neovascular AMD leads to severe vision loss, and cell therapies have shown limited success in replacing dysfunctional retinal pigment epithelium (RPE) cells.
Innovation Solution
The use of orbital fat-derived mesenchymal stem cells (OMSCs) expressing specific surface markers (CD73, CD90, CD105, and lacking CD45) to treat oxidative-stress related-damage of RPE cells, enhancing their oxidative stress-protecting activity through methods that include contacting stressed RPE cells with these cells or their conditioned medium, and potentially using a scaffold for cell delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (lifestyle modification and vitamin supplements) are used for non-neovascular AMD, then disease progression is slowed, but damage to the macula cannot be reversed
Solution Approach 1:
The patent uses orbital fat-derived mesenchymal stem cells as intermediary agents that deliver protective factors and promote RPE cell survival. These cells act as mediators between the therapeutic goal and the damaged tissue, providing trophic support and reducing oxidative stress without directly replacing the RPE cells.
Solution Approach 2:
The treatment leverages the body's own orbital fat tissue as a source of mesenchymal stem cells, enabling autologous transplantation. This self-service approach eliminates the need for external donors and reduces immunogenicity, while the cells themselves provide self-protective mechanisms against oxidative stress.
2Ease of manufacture
If cell therapy is used to replace dysfunctional RPE cells, then potential for reversing damage is improved, but current cell therapies have shown limited success
Solution Approach 1:
The patent changes the parameters of cell therapy by selecting a specific cell source (orbital fat-derived mesenchymal stem cells) with unique properties including neural crest origin, high differentiation potential to RPE, and resistance to oxidative stress. These parameter changes distinguish the therapy from previous attempts using other cell types.
Solution Approach 2:
The treatment converts the presence of orbital fat (often considered excess tissue) into a valuable therapeutic resource. By harvesting mesenchymal stem cells from orbital fat, the patent transforms what is typically viewed as waste tissue into a source of protective cells that can prevent and reverse RPE damage.
3Reliability
If Anti-VEGF antibodies are used to treat neovascular AMD, then further vision deterioration is prevented, but curative treatment is not achieved
Solution Approach 1:
The patent employs mesenchymal stem cells as intermediary agents that deliver multiple therapeutic effects simultaneously, including anti-oxidative protection, anti-inflammatory effects, and promotion of RPE survival. This multi-faceted intermediary approach addresses the limitations of single-target Anti-VEGF therapy.
Solution Approach 2:
The mesenchymal stem cells provide multiple functions: they protect against oxidative stress, reduce inflammation, promote RPE cell survival, and can differentiate into RPE-like cells. This multi-functionality allows a single therapy to address multiple aspects of AMD pathogenesis that cannot be targeted by Anti-VEGF alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
OMSCs effectively prevent RPE degeneration, enhance Müller cell activation, increase retinal intactness, promote microglia migration, and improve photoreceptor layer health, thereby treating AMD and reversing some of the associated vision loss.
Implementation Method 1
treating oxidative-stress related-damage of retinal pigment epithelium (RPE) cells
Data Source
AI summary
The present invention is directed to compositions for treating oxidative-stress related-damage of retinal pigment epithelium (RPE) cells by contacting orbital fat-derived mesenchymal cell with the damaged RPE cells.